ALCL, anaplastic large cell lymphoma; ALL, acute lymphoblastic leukemia; CLL, chronic lymphocytic leukemia; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; CML, chronic myeloid leukemia; HL, Hodgkin’s lymphoma; NHL, non-Hodgkin’s lymphoma; DLBCL, diffuse large B-cell lymphoma; MM, multiple myeloma; NK, natural killer; PRF1, perforin 1 gene; NKG2D, natural killer group 2D; NKG2DL, NKG2D ligands; NKp30, 44, 46, natural killer P30, 44, 46; TIM-3, T cell immunoglobulin domain, mucin domain; FASLG, Fas ligand gene; ULBP1, UL16 binding proteins 1; NKG2A, natural killer group 2A. This evidence concerns the gene ULBP1 and chronic myelogenous leukemia, BCR-ABL1 positive.